# Effectiveness of Whey Protein Supplementation in Weight Loss Interventions for Patients with Obesity: A Systematic Review

**Authors:** Juan José López-Gómez, Beatriz Ramos-Bachiller, Daniel Rico-Bargues, Daniel A. De Luis-Román

PMC · DOI: 10.3390/nu18040695 · Nutrients · 2026-02-21

## TL;DR

This study reviews whether whey protein helps preserve muscle mass during weight loss in obese adults.

## Contribution

A systematic review evaluating whey protein's role in preserving fat-free mass during obesity weight loss interventions.

## Key findings

- Whey protein may help maintain fat-free mass, especially with resistance exercise or anabolic additives.
- Effectiveness varied, with neutral results when physical activity was absent.
- Evidence certainty was low due to small samples, short durations, and methodological issues.

## Abstract

Background: Obesity is traditionally defined by excess fat mass; however, the preservation of fat-free mass (FFM), particularly skeletal muscle, has gained increasing relevance due to its metabolic, endocrine, and functional roles. Weight loss interventions, including hypocaloric diets, pharmacological treatments, and bariatric surgery, are frequently associated with unintended loss of skeletal mass, increasing the risk of sarcopenic obesity and related complications. Objective: This study aimed to systematically evaluate the effectiveness of whey protein supplementation in preserving fat-free mass and muscle-related outcomes in adults with obesity undergoing weight loss interventions. Methods: A systematic review was conducted in accordance with PRISMA guidelines. Randomized controlled trials published in English were identified through searches of PubMed/MEDLINE, CENTRAL, Embase, Scopus, ClinicalTrials.gov, and WHO ICTRP, searched up to September 2025. Eligible studies included adults (>18 years) with obesity receiving whey protein supplementation as part of a hypocaloric diet, compared with placebo or standard interventions. Primary outcomes were changes in fat-free mass assessed by validated methods (DXA, BIA, MRI), while secondary outcomes included body weight, fat mass, metabolic parameters, adherence, and safety. Risk of bias was assessed using the Cochrane RoB 2.0 tool, and certainty of evidence was evaluated with GRADE. The abstract was registered in PROSPERO with code CRD420251069996. There was no funding and no conflicts of interest. Results: Fourteen randomized controlled trials were included. Whey protein supplementation generally supported the maintenance or modest improvement of fat-free mass, particularly when combined with resistance exercise or anabolic-enriched formulations such as leucine or vitamin D. Several trials, however, reported neutral effects, especially in the absence of structured physical activity. Overall, effect estimates ranged from small gains to null or uncertain differences, and the certainty of evidence was frequently downgraded due to limited sample sizes, wide confidence intervals, heterogeneity across interventions and assessment methods, short follow-up periods, and methodological limitations including open-label designs and inconsistent adherence monitoring. Conclusions: Whey protein supplementation may support fat-free mass preservation during weight loss in adults with obesity, particularly as part of a multimodal intervention. Further high-quality trials are needed to define optimal dosing strategies and target populations.

## Linked entities

- **Diseases:** obesity (MONDO:0011122)

## Full-text entities

- **Genes:** INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, GLP1R (glucagon like peptide 1 receptor) [NCBI Gene 2740] {aka GLP-1, GLP-1-R, GLP-1R}
- **Diseases:** fat (MESH:D004620), body weight reduction (MESH:D001835), metabolic (MESH:D008659), loss of skeletal mass (MESH:C536030), type 2 diabetes (MESH:D003924), weight regain (MESH:D055191), adiposity (MESH:D018205), Obesity (MESH:D009765), falls (MESH:C537863), muscle deterioration (MESH:D009135), overweight (MESH:D050177), renal failure (MESH:D051437), Protein deficiency (MESH:D011488), cardiovascular disease (MESH:D002318), diabetes (MESH:D003920), intestinal dysbiosis (MESH:D064806), cancer (MESH:D009369), prediabetes (MESH:D011236), liver cirrhosis (MESH:D008103), Weight Loss (MESH:D015431), chronic kidney disease (MESH:D051436), insulin resistance (MESH:D007333), injury to (MESH:D014947), Sarcopenia (MESH:D055948), chronic liver disease (MESH:D008107), chronic inflammation (MESH:D007249), a loss of strength (MESH:D016388), metabolic disturbances (MESH:D024821), nutrient malabsorption (MESH:D008286), impaired physical function (MESH:D059445), fractures (MESH:D050723), malnutrition (MESH:D044342), muscle catabolism (MESH:D019042)
- **Chemicals:** Essential Amino Acid (MESH:D000601), glucose (MESH:D005947), calcium (MESH:D002118), leucine (MESH:D007930), prebiotics (MESH:D056692), lipid (MESH:D008055), hydroxymethylbutyrate (MESH:C004961), vitamin D3 (MESH:D002762), isoflavones (MESH:D007529), carbohydrate (MESH:D002241), Iso (-), Fat (MESH:D005223), vitamin D (MESH:D014807), maltodextrin (MESH:C008315)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12942925/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12942925/full.md

## References

41 references — full list in the complete paper: https://tomesphere.com/paper/PMC12942925/full.md

---
Source: https://tomesphere.com/paper/PMC12942925